N'-[(E)-(5-bromo-2-methoxyphenyl)methylidene]-2-[(1-ethyl-1H-benzimidazol-2-yl)thio]acetohydrazide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N'-[(E)-(5-bromo-2-methoxyphenyl)methylidene]-2-[(1-ethyl-1H-benzimidazol-2-yl)thio]acetohydrazide
• 英文别名: N-[(E)-(5-bromo-2-methoxyphenyl)methylideneamino]-2-(1-ethylbenzimidazol-2-yl)sulfanylacetamide
• 化学式: C₁₉H₁₉BrN₄O₂S
• 分子量: 447.4
• InChiKey: ZVPBJSLVOLOXMK-SRZZPIQSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  93.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• CHEMICAL INHIBITORS OF SOLUBLE ADENYLYL CYCLASE (SAC)
  申请人：CORNELL RESEARCH FOUNDATION, INC.

  公开号：EP1706114B1

  公开（公告）日：2012-12-26
• Chemical Inhibitors of Soluble Adenylyl Cyclase (Sac)
  申请人：Buck Jochen

  公开号：US20070244174A1

  公开（公告）日：2007-10-18

  The present invention relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject. The method involves administering to a subject an effective amount of a compound disclosed herein that modulates soluble adenylyl cyclase, under conditions effective to treat the disorder mediated by soluble adenylyl cyclase. The present invention also relates to a method of treating a disorder mediated by soluble adenylyl cyclase in a subject, where the disorder is selected from the group consisting of: learning or memory disorders, malaria, fungal infection, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, and peripheral neuropathy. The method involves modulating soluble adenylyl cyclase in the subject. Another aspect of the present invention relates to a method of modulating soluble adenylyl cyclase. The method involves contacting eukaryotic cells with a compound that modulates soluble adenylyl cyclase, under conditions effective to modulate soluble adenylyl cyclase.
• US9649295B2
  申请人：——

  公开号：US9649295B2

  公开（公告）日：2017-05-16